Document ID: FDA-2019-N-1346-0003
Agency: fda
Document Type: Notice
Title: Development of Antiviral Drugs for the Treatment of Adenoviral Infection in Immunocompromised Patients; Public Workshop; Cancellation
Posted Date: 2019-07-12T04:00Z

[Federal Register Volume 84, Number 134 (Friday, July 12, 2019)]
[Notices]
[Page 33267]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-14887]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-N-1346]

Development of Antiviral Drugs for the Treatment of Adenoviral 
Infection in Immunocompromised Patients; Public Workshop; Cancellation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration is announcing the 
cancellation of a public workshop entitled ``Development of Antiviral 
Drugs for the Treatment of Adenoviral Infection in Immunocompromised 
Patients'' that was previously scheduled for August 8, 2019, from 8:30 
a.m. to 4:30 p.m. This public workshop was announced in the Federal 
Register of May 2, 2019. The meeting has been cancelled due to 
unforeseen changes in the adenovirus drug development landscape.

FOR FURTHER INFORMATION CONTACT: Lori Benner and/or Jessica Barnes, 
Center for Drug Evaluation and Research, Food and Drug Administration, 
10903 New Hampshire Ave., Bldg. 22, Rm. 6221, Silver Spring, MD 20993-
0002, 301-796-1300, about this public workshop, which was announced in 
the Federal Register of May 2, 2019 (84 FR 18848).

    Dated: July 8, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-14887 Filed 7-11-19; 8:45 am]
BILLING CODE 4164-01-P